Company news
Pyc Therapeutics Limited (ASX:PYC) news
Pyc Therapeutics Limited news releases on 6ix. Latest, Mar 2, 2021: Lead Investigational Drug Demonstrates Key Improvement
Press releases — page 3
Lead Investigational Drug Demonstrates Key Improvement
March 1, 2021
Half Year Accounts and Appendix 4D
February 26, 2021
Progress US Clinical Stage Company and Corporate Objectives
February 21, 2021
Quarterly Activities Report and Appendix 4C
January 29, 2021
Visual Evidence of Lead Drugs Efficacy
December 15, 2020
Review of Activities and Appendix 4C
October 26, 2020
Successful Institutional Entitlement Offer and Placement
October 21, 2020
PYC Business and Equity Raising Presentation
October 19, 2020
New Drug for Substantial Unmet Need Added to Pipeline
October 11, 2020
PYCs Lead Drug Effective in Patient Derived Models Tested
October 6, 2020
Second Potential Blockbuster Drug Added to PYCs Pipeline
October 4, 2020
Creation of Novel Gene Therapy Delivery Technology
September 7, 2020
Appendix 4E Preliminary Final Report
August 31, 2020
Executive re-structure across global operations
August 19, 2020
Shareholder Update - Forward View 2020 Milestones
August 4, 2020
June 2020 Quarterly Activity Report and Cashflow
July 30, 2020
Successful Dose Response & Toxicity Studies in Lead Program
July 21, 2020
S&P DJI Announces June 2020 Quarterly Rebalance
June 11, 2020
March 2020 Quarterly Activities and Cash Flow Report
April 29, 2020
Successful Efficacy Result on Path to First in Human Studies
March 31, 2020
Investor Presentation - February 2020
February 23, 2020
CEO Appointment and Establishment of US Office
February 12, 2020
Expansion Of Drug Development Pipeline
February 2, 2020
Appendix 4C - quarterly
January 31, 2020
Quarterly Shareholder Update
January 5, 2020
Drug Delivery Greater Than 100% More Effective In Animals
December 1, 2019
Conclusion of Genentech Antimicrobial Collaboration
November 14, 2019
Retail Offer Document
November 3, 2019
Entitlement Offer - Investor Presentation
October 31, 2019
$26.8m Fully Underwritten Accelerated Entitlement Offer
October 30, 2019
Successful Major Milestone - Human Retina in a Dish Models
October 8, 2019
Strategic Partnership and Lead Program
October 1, 2019
Successful Time-Course Studies in Animals
September 25, 2019
Successful Competitive Drug Evaluation in Animals
September 2, 2019
Successful Time - Course Studies in Animals
August 22, 2019
Response to ASX Aware Query
August 7, 2019
Phylogicas Technology is Effective in Human Cells
August 6, 2019
Company Presentation - July 2019
July 23, 2019
Animal Models - 400% Outperformance of Gold Standard
July 22, 2019
Break Through Animal Model Results
June 26, 2019
March 2019 Quarterly Operational Update and App4C
April 29, 2019
Collaboration Agreement - siRNA delivery
March 13, 2019
Flagship Program - Successful Animal Models
March 11, 2019
First Competitive Read Out - Peptide Vaccine
February 8, 2019
Dec 2018 Operational Update and App4C
January 31, 2019
CEO letter and Operational Update
January 16, 2019
In Vivo Success - peptide vaccine (Amended Graphics)
December 6, 2018
Successful Delivery of CRIPR/Cas9 into Cells ex vivo
December 3, 2018
FNA Presentation
November 22, 2018
AGM Company Presentation
November 16, 2018